Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan.

MLA

Yoshimura, Akihiro, et al. “Clinical Outcomes of First-Line Combination Therapy with Immune Checkpoint Inhibitor for Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study in Japan.” International Journal of Clinical Oncology, vol. 29, no. 12, Dec. 2024, pp. 1916–24. EBSCOhost, https://doi.org/10.1007/s10147-024-02612-1.

APA

Yoshimura, A., Kato, T., Nakai, Y., Tsujihata, M., Toyoda, S., Sato, M., Matsuzaki, K., Nakata, W., Takao, T., Inoguchi, S., Okuda, Y., Yamamichi, G., Ishizuya, Y., Yamamoto, Y., Hatano, K., Kawashima, A., Takada, S., Inoue, H., Nishimura, K., & Miyake, O. (2024). Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan. International Journal of Clinical Oncology, 29(12), 1916–1924. https://doi.org/10.1007/s10147-024-02612-1

Chicago

Yoshimura, Akihiro, Taigo Kato, Yasutomo Nakai, Masao Tsujihata, Shingo Toyoda, Mototaka Sato, Kyosuke Matsuzaki, et al. 2024. “Clinical Outcomes of First-Line Combination Therapy with Immune Checkpoint Inhibitor for Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study in Japan.” International Journal of Clinical Oncology 29 (12): 1916–24. doi:10.1007/s10147-024-02612-1.